Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Radiol ; 61(3): 499-506, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17166681

ABSTRACT

Hereditary Hemochromatosis is the most frequent modality of iron overload. Since 1996 genetic tests have facilitated significantly the non-invasive diagnosis of the disease. There are however many cases of negative genetic tests that require confirmation by hepatic iron quantification which is traditionally performed by hepatic biopsy. There are many studies that have demonstrated the possibility of performing hepatic iron quantification with Magnetic Resonance. However, a consensus has not been reached yet regarding the technique or the possibility to reproduce the same method of calculus in different machines. This article reviews the state of the art of the question and delineates possible future lines to standardise this non-invasive method of hepatic iron quantification.


Subject(s)
Hemochromatosis/diagnosis , Iron/metabolism , Liver/metabolism , Magnetic Resonance Imaging , Hemochromatosis/genetics , Hemochromatosis/metabolism , Humans
2.
J Intensive Care Med ; 21(1): 27-39, 2006.
Article in English | MEDLINE | ID: mdl-16698742

ABSTRACT

The objective was to evaluate the efficacy and safety of recombinant activated factor VII in patients with massive bleeding. Forty-five patients with severe massive hemorrhage requiring>or= 14 transfusion units of packed red blood cells received recombinant activated factor VII. Postdrug blood loss and transfusion requirements were assessed, and mortality was compared with predicted outcomes. Blood loss was markedly reduced in 40 of 43 (93.0%) patients, and transfusion requirements decreased after recombinant activated factor VII administration. Mortality rate in trauma patients who had massive hemorrhage was significantly reduced compared with predictions using scoring systems. This may be associated with the use of recombinant activated factor VII. This study failed to demonstrate an improvement in surgical patients. The absence of concurrent controls prevents definitive conclusions regarding actual safety or efficacy of recombinant activated factor VII.


Subject(s)
Blood Loss, Surgical/prevention & control , Factor VIIa/therapeutic use , Hemorrhage/drug therapy , Hemorrhage/etiology , Wounds and Injuries/complications , Adolescent , Adult , Aged , Canada , Dose-Response Relationship, Drug , Europe , Female , Hemostatic Techniques , Humans , Injury Severity Score , Male , Middle Aged , Registries , Risk Assessment/methods , Survival Analysis , Treatment Outcome , Wounds and Injuries/classification
SELECTION OF CITATIONS
SEARCH DETAIL
...